# InpharmD

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inpharmd

- Industry: Healthcare IT
- Headquarters: Atlanta, US
- Website: www.inpharmd.com
- Total disclosed funding: $8.3M
- Latest round: Seed (Oct 24, 2023)
- Investors on record: 5

## About

Based in Georgia, US, and founded in 2018 by co-founder and CEO Ashish Advani, InpharmD, Inc. operates as a healthcare IT company that focuses on developing a healthcare information platform intended to help healthcare providers. The company's platform, powered by artificial intelligence, collects all medical information to help healthcare providers make better decisions. In December 2023, InpharmD, Inc. raised USD 6.05 million in seed funding led by 645 Ventures, with participation from Atlanta Ventures, Y Combinator, Qlarant Capital, and SF ELC.

The company provides an artificial intelligence (AI)-based drug information platform to healthcare providers, enabling them to ask any clinical question and receive a curated, data-driven answer. InpharmD uses natural language processing to consolidate clinical literature and summarize applicable content. In addition, the firm also provides a robust pharmacy and therapeutics arm that focuses on the creation of comprehensive drug monographs, class reviews, formulary management, and more.

InpharmD plans to use its proceeds from December 2023 funding to further develop its product and to perfect its AI model for point-of-care decision support.

## Funding rounds

- Seed, Oct 24, 2023, $8.3M — Y Combinator, Atlanta Ventures, 645 Ventures, ELC, Qlarant Capital

## Investors

- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed
- Atlanta Ventures (https://capitalatlas.ai/funds/atlanta-ventures) — Seed
- 645 Ventures (https://capitalatlas.ai/funds/645-ventures) — Seed
- ELC — Seed
- Qlarant Capital (https://capitalatlas.ai/funds/qlarant-capital) — Seed